Skip to main content
SpringerLink
Log in

Anticardiolipin antibodies and lupus anticoagulant in patients treated with different methods of renal replacement therapy in comparison to patients with systemic lupus erythematosus

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Summary

Antiphospholipid antibodies were found to be associated with certain clinical manifestations such as recurrent venous thrombosis or arterial occlusions in a wide spectrum of immune disorders [6]. We analyzed the plasma concentration of two isotypes (IgG, IgM) of anticardiolipin antibodies (ACA) and lupus anticoagulant (LAC) activity in 84 patients with end-stage renal disease. They were receiving different types of renal replacement therapy and had a high frequency of thrombotic vascular complications. The prevalence of positive tests and the mean ACA concentration obtained in the plasma of renal patients were compared with those in patients with systemic lupus erythematosus (SLE) and in healthy controls. When analyzed as a whole group, renal patients maintained on dialysis (n=45: hemodialysis,n=20; peritoneal dialysis) or with a functioning kidney transplant (n=19) did not differ in mean ACA concentration and LAC activity (n=84, ACA: IgG 10±7 U/ml, IgM 2±1 U/ml, LAC ratio: 1.0±0.2) from healthy subjects (n=50, ACA: IgG 10±3, IgM 2±1 U/ml, LAC ratio: 1.0±0.1) but they had a higher incidence of raised IgG-ACA titers (renal replacement 14% vs. normal controls 4%,p<0.05). No significant correlation was found between thrombotic events and raised ACA or LAC activity in dialysis patients. In contrast, the proportion of SLE patients (n=51) with a raised concentration of ACA was significantly higher (IgG: 69%, IgM: 29%) than that among patients with renal replacement therapy (IgG: 14%, IgM: 4%) or normal controls (IgG: 4%, IgM: 2%,p<0.002). Moreover, recurrent manifestations of thrombosis in SLE were associated with very high IgG-ACA (n=11, IgG 117±91 U/ml) and LAC activity (LAC ratio: 2.4±0.7) in comparison to SLE patients without thrombotic events (n=40, ACA: IgG 23±13). The results of our investigations demonstrate that the pathogenetic role of these phospholipid antibodies in end-stage renal disease is far from established.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Alarcon-Segovia D, Sanchez-Guerrero J (1989) Primary antiphospholipid syndrome. J Rheumatol 16: 482–488

    PubMed  Google Scholar 

  2. Alarcon-Segovia D, Deleze M, Oria CV, Sanchez-Guerrero J, Gomez-Pacheco L, Cabiedes J, Fernandez L, Ponce de Leon S (1989) Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine 68: 353–365

    PubMed  Google Scholar 

  3. Ashley S, Kruger A, McMullen KW, Darke S (1988) Prosthetic graft thrombosis associated with lupus anticoagulant. Eur J Vasc Surg 2: 57–60

    PubMed  Google Scholar 

  4. Boey ML, Colaco CB, Gharavi AE, Elkon KB, Loizou S, Hughes GRV (1983) Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant. Br Med J 287: 1021–1023

    Google Scholar 

  5. Brunner FP, Brynger H, Ehrich JHH et al. (1989) Combined report on regular dialysis and transplantation in Europe. XIX. Nephrol Dial Transplant 4 [Suppl 4]: 5–40

    Google Scholar 

  6. Cameron JS, Frampton G (1990) The “antiphospholipid syndrome” and the “lupus anticoagulant”. Pediatr Nephrol 4: 663–678

    PubMed  Google Scholar 

  7. Cervera R, Font J, Lopez-Soto A, Casals F, Pallares L, Bove A, Ingelmo M, Urbano-Marquez A (1990) Isotype distribution of anticardiolipin antibodies in systemic lupus erythematosus: prospective analysis of a series of 100 patients. Ann Rheum Dis 49: 109–113

    PubMed  Google Scholar 

  8. Cronin ME, Biswas RM, Van der Straeton C, Fleisher TA, Klippel JH (1988) IgG and IgM anticardiolipin antibodies in patients with lupus with anticardiolipin antibody-associated clinical syndromes. J Rheumatol 15: 795–798

    PubMed  Google Scholar 

  9. Exner T, Triplett DA, Taberner D, Machin SJ (1991) Guidelines for testing and revised criteria for lupus anticoagulants. SCC Subcommittee for the standardization of lupus anticoagulants. Thromb Haemost 65: 320–322

    PubMed  Google Scholar 

  10. Garcia-Martin F, De Arriba G, Carrascosa T, Moldenhauer F, Martin-Escobar E, Val J, Saiz F (1991) Anticardiolipin antibodies and lupus anticoagulant in end-stage renal disease. Nephrol Dial Transplant 6: 543–547

    PubMed  Google Scholar 

  11. Grönhagen-Riska C, Teppo AM, HelanterÄ A, Honkanen E, Julkunen H (1990) Raised concentrations of antibodies to cardiolipin in patients receiving dialysis. Br Med J 300: 1996–1997

    Google Scholar 

  12. Hakim RM, Lazarus IM (1986) Medical aspects of hemodialysis. In: Brenner BM, Rector FC (eds) The kidney. Saunders, Philadelphia, pp 1791–1845

    Google Scholar 

  13. Hamsten A, Norberg R, Björkholm M, De Faire U, Holm G (1986) Antibodies to cardiolipin in young survivors of myocardial infarction: an association with recurrent cardiovascular events. Lancet 1: 113–116

    PubMed  Google Scholar 

  14. Harris EN, Garavi AE, Boey ML, Patel BM, Mackworth-Young CG, Loizou S, Hughes GRV (1983) Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 2: 1211–1214

    PubMed  Google Scholar 

  15. Koblmüller A, Breitenfellner P, Leitner E, Stumvoll HK, Kapiotis S (1991) Antikardiolipinantikörper bei Dialysepatienten. Nieren Hochdruckkrankheiten 20: 235

    Google Scholar 

  16. Mackworth-Young C (1990) Antiphospholipid antibodies: more than just a disease marker? Immunol Today 11: 60–65

    PubMed  Google Scholar 

  17. Miles TJ, Safford RE, Kazmier FJ (1988) Myocardial infarction, persistent coronary artery thrombosis and lupus anticoagulant. Int J Casrdiol 21: 1990–1994

    Google Scholar 

  18. Santiano MB, Cossermelli W, Tuma MF, Pinto MN, Oliveira RM (1989) Anticardiolipin antibodies in patients with infectious diseases. Clin Rheumatol 8: 23–38

    PubMed  Google Scholar 

  19. Tan EM, Cohen AS, Fries JF, et al. (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25: 1271–1277

    PubMed  Google Scholar 

  20. Vaarala O, Palosuo T, Klemola M, Aho K (1986) Anticardiolipin response in acute infections. Clin Immunol Immunopathol 41: 8–15

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik, Klinikum Innenstadt der UniversitÄt München, Ziemssenstrasse 1, W-8000, München 2, FRG

    T. Sitter, M. Spannagl & H. Schiffl

Authors
  1. T. Sitter
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Spannagl
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Schiffl
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sitter, T., Spannagl, M. & Schiffl, H. Anticardiolipin antibodies and lupus anticoagulant in patients treated with different methods of renal replacement therapy in comparison to patients with systemic lupus erythematosus. Ann Hematol 65, 79–82 (1992). https://doi.org/10.1007/BF01698134

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01698134

Key words

Search

Navigation